Heartflow Inc(HTFL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:46 PM ET (Korea 10/31 07:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.4 | Insider Own | 25.4% | Shs Outstand | 86.7M | Perf Week | 4.23% |
| Market Cap | 5.14B | Forward P/E | - | EPS next Y | 34.69% | Insider Trans | -10% | Shs Float | 64.9M | Perf Month | 20.85% |
| Enterprise Value | 5.00B | PEG | - | EPS next Q | -0.1 | Inst Own | 82.91% | Short Float | 11.3% | Perf Quarter | 120.89% |
| Income | -0.12B | P/S | 24.24 | EPS this Y | 74.43% | Inst Trans | 35.22% | Short Ratio | 3.9 | Perf Half Y | 106.17% |
| Sales | 0.21B | P/B | 18.32 | EPS next 5Y | - | ROA | -46.99% | Short Interest | 7.33M | Perf YTD | 102.78% |
| Book/sh | 3.23 | P/C | 31.62 | EPS past 3/5Y | 5.2% - | ROE | -154.23% | 52W High | -2.39% ($60.56) | Perf Year | 61.64% |
| Cash/sh | 1.87 | P/FCF | - | Sales past 3/5Y | 42.1% - | ROIC | -39.45% | 52W Low | 193.64% ($20.13) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | 80.08% | Volatility(W/M) | 5.06% 5.92% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 23.6 | Sales Y/Y TTM | - | Oper. Margin | -34.31% | ATR (14) | 2.89 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.87 | EPS Q/Q | -65.19% | Profit Margin | -55.82% | RSI (14) | 67.53 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.87 | Sales Q/Q | 47.57% | SMA20 | 10.77% ($53.36) | Beta | 2.68 | Target Price | $50.5 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/11/12 | SMA50 | 16.31% ($50.82) | Rel Volume | 1.19 | Prev Close | $60.53 |
| Employees | 843 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 47.64% 13.15% | SMA200 | 73.26% ($34.12) | Avg Volume(3M) | 1.88M | Price | $59.11 |
| IPO | 2025/8/8 | Option/Short | Yes/Yes | Trades | 16066 | Volume | 2,246,004 | Change | -2.35% |
A US healthcare information company that provides an AI-powered, non-invasive diagnostic solution for coronary artery disease. The company offers a precision diagnostic platform that uses artificial intelligence to analyze cardiac imaging data, enabling non-invasive assessment of coronary blood flow, stenosis, and atherosclerotic plaque. It has established a strong position with a differentiated solution that evaluates coronary artery disease without the need for invasive procedures.
Over the past 1 year, on the higher side
2% below its 1-year high.
Traded about as much as usual. That is 119% of its average volume.
Next earnings report: November 12
13 days to go.
HTFL has a sound balance sheet but weak earning power
Of every $100 in sales, $34.31 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,424. Peers typically go for $182.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 82.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #8 of 41 in the industry
Based on market cap of $5B.
FAQ
What kind of company is HTFL?
HTFL belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of HTFL?
The market cap of HTFL is approximately $5.1B, ranking 1,354 within its sector.
What is the 52-week high and low for HTFL?
HTFL has recorded a 52-week high of $60.56 and a low of $20.13.
